Join
Live feed
·
PRReleasevia Quantisnow
Autolus Therapeutics plc logo

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

ByQuantisnow·Wall Street's wire, on your screen.
AUTL· Autolus Therapeutics plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AUTL (Autolus Therapeutics plc) and more on Quantisnow.